Skip to main content

Advertisement

SpringerLink
Log in

Intravesical therapy for overactive bladder

  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic therapy. Despite the development of new antimuscarinic agents, many patients do not tolerate or fail to respond to oral therapy. Intravesical instillation therapy can provide an alternative method of managing bladder overactivity. Intravesical instillation of anticholinergics such as oxybutynin and atropine can achieve cholinergic blockade without producing systemic side effects. Botulinum A toxin injected directly into the detrusor has been shown in preliminary studies to increase bladder capacity and decrease uncontrolled bladder contractility for up to 6 months. Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers and when administered into the bladder, lead to an increase in functional bladder capacity. Intravesical capsaicin and resiniferatoxin also affect afferent innervation by blocking C-fiber afferents, leading to decreased bladder contractility and increased bladder capacity. Intravesical instillation therapy can provide an alternative treatment for the management of overactive bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Chapple CR: Muscarinic antagonists in the treatment of overactive bladder. Urology 2000, 55(suppl 5A):33–46.

    Article  PubMed  CAS  Google Scholar 

  2. Fowler CJ: Intravesical treatment of overactive bladder. Urology 2000, 55(suppl 5A):60–64.

    Article  PubMed  CAS  Google Scholar 

  3. Yoshimura N, Chancellor MB: Current and future pharmacological treatment of overactive bladder. J Urol 2002, 168:1897–1913.

    Article  PubMed  CAS  Google Scholar 

  4. Brendler CB, Radebaugh LC, Mohler JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989, 141:1350–1352.

    PubMed  CAS  Google Scholar 

  5. Madersbacher H, Jilg G: Control of detrusor hyperreflexia by the intravesical solution of oxybutynin hydrochloride. Paraplegia 1991, 29:84–90.

    PubMed  CAS  Google Scholar 

  6. Massad CA, Kogan BA, Trigo-Rocha FE: The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992, 148:595–597.

    PubMed  CAS  Google Scholar 

  7. Lehtoranta K, Tainio H, Lukkari-Lax E, et al.: Pharmacokinetics efficacy and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002, 36:18–24.

    Article  PubMed  CAS  Google Scholar 

  8. Buyse G, Waldeck K, Verpoorten C, et al.: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160:892–896.

    Article  PubMed  CAS  Google Scholar 

  9. Greenfield SP, Fera M: The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 1991, 146:532–534.

    PubMed  CAS  Google Scholar 

  10. Weese DL, Roskamp DA, Leach GE, et al.: Intravesical oxybutynin chloride: experience with forty-two patients. Urology 1993, 41:527–530.

    Article  PubMed  CAS  Google Scholar 

  11. Kasabian NG, Vlachiotis JD, Lais A, et al.: The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyper-reflexia. J Urol 1994, 151:944–945.

    PubMed  CAS  Google Scholar 

  12. Painter KA, Vates TS, Bukowski TP, et al.: Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J Urol 1996, 156:1459–1462.

    Article  PubMed  CAS  Google Scholar 

  13. Palmer LS, Zebold, K, Firlit CF, et al.: Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 1997, 157:638–640.

    Article  PubMed  CAS  Google Scholar 

  14. Haferkamp PA, Stachler J, Gerner HJ, et al.: Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 2000, 38:250–254.

    Article  PubMed  CAS  Google Scholar 

  15. O Flynn KJ, Thomas DG: Intravesical instillation of oxybutynin hydrochloride for detrusor hyperreflexia. Br J Urol 1993, 72:566–570.

    CAS  Google Scholar 

  16. DeWachter S, Wyndaele JJ: Intravesical oxybutynin: a local anesthetic effect on bladder c afferents. J Urol 2003, 169:1892–1895.

    Article  CAS  Google Scholar 

  17. Pannek J, Sommerfeld HJ, Botel U, et al.: Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000, 55:I358-I362.

    Article  Google Scholar 

  18. Glickman S, Tsokkos N, Shah PJ: Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder: a preliminary study. Paraplegia 1995, 33:36–39.

    PubMed  CAS  Google Scholar 

  19. Deaney C, Glickman S, Gluck T, et al.: Intravesical atropine suppression of detrusor hyperreflexia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 65:957–958.

    Article  PubMed  CAS  Google Scholar 

  20. Enskat R, Deaney CN, Glickman S: Systemic effects of intravesical atropine sulfate. BJU Int 2001, 81:613–616.

    Article  Google Scholar 

  21. Schurch B, Stöhrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692–697.

    Article  PubMed  CAS  Google Scholar 

  22. Schurch B, Schmid DM, Stöhrer M: Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000, 342:665.

    Article  PubMed  CAS  Google Scholar 

  23. Schulk-Baukloh H, Michael T, Schobert T, et al.: Efficacy of botulinum toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002, 59:325–327.

    Article  Google Scholar 

  24. Reitz A, Schurch B: Intravesical therapy option for neurogenic detrusor overactivity. Spinal Cord 2004, 42:267–272.

    Article  PubMed  Google Scholar 

  25. Yokoyama O, Kimatu K, Kodama K, et al.: Diagnostic value of intravesical lidocaine for overactive bladder. J Urol 2000, 164:340–343.

    Article  PubMed  CAS  Google Scholar 

  26. Lapointe SP, Wang B, Kennedy WA, et al.: The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele. J Urol 2001, 165:2380–2382.

    Article  PubMed  CAS  Google Scholar 

  27. McInemey PD, Grant A, Chawla J, et al.: The effect of intravesical Marcaine instillation on hyperreflexic detrusor contractions. Paraplegia 1992, 30:127–130.

    Google Scholar 

  28. Yokoyama O, Ishura T, Nakamura T, et al.: Urodynamic effects of intravesical instillation of lidocaine in patients with overactive detrusor. J Urol 1997, 159:1826–1830.

    Google Scholar 

  29. Chancellor MB, deGroat WC: Intravesical capsaicin and resiniferatoxin therapy: spicing up ways that we treat the overactive bladder. J Urol 1999, 162:3–11.

    Article  PubMed  CAS  Google Scholar 

  30. Caterina MJ, Schumacher MA, Tominaga M, et al.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816–824.

    Article  PubMed  CAS  Google Scholar 

  31. Fowler CJ, Jewkes D, McDonald WI, et al.: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992, 339:1239.

    Article  PubMed  CAS  Google Scholar 

  32. Wiart L, Joseph P, Petit H, et al.: The effects of capsaicin on the neurogenic hyperreflexic detrusor: a double-blind, placebo-controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord 1998, 36:95–99.

    Article  PubMed  CAS  Google Scholar 

  33. deSeze M, Wiart L, Joseph P, et al.: Capsaicin and neurogenic detrusor hyperreflexia: a double-blind, placebo-controlled study in twenty patients with spinal cord lesions. Neurourol Urodyn 1998, 17:513–523.

    Article  CAS  Google Scholar 

  34. de Seze M, Wiart L, Ferriere J, et al.: Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 1999, 36:267–277.

    Article  PubMed  Google Scholar 

  35. DeRidder D, Chandiramani V, Dasgupta P, et al.: Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a duel center study with long-term follow-up. J Urol 1997, 158:2087–2092.

    Article  CAS  Google Scholar 

  36. Avelino A, Cruz F, Colimbra A: Lidocaine prevents noxious excitation of bladder afferents induced by intravesical capsaicin without interfering with the ensuing sensory desensitization: an experimental study in the rat. J Urol 1998, 159:567–570.

    Article  PubMed  CAS  Google Scholar 

  37. Cruz F, Guimares M, Silva C, et al.: Desensitization of bladder sensory fibers by intravesical capsaicin has long-lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. J Urol 1997, 157:585–589.

    Article  PubMed  CAS  Google Scholar 

  38. Cruz F, Guimares M, Silva C, et al.: Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet 1993, 350:640–641.

    Article  Google Scholar 

  39. Lazzeri M, Spinelli M, Beneforti P, et al.: Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord disease. Scand J Urol Nephrol 1998, 32:331–334.

    Article  PubMed  CAS  Google Scholar 

  40. Silva C, Rio ME, Cruz F: Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000, 38:444–452.

    Article  PubMed  CAS  Google Scholar 

  41. DeSeze M, Wairt L, deSeze MP, et al.: Intravesical capsaicin vs resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004, 171:251–255.

    Article  CAS  Google Scholar 

  42. Lazzeri M, Spinelli M, Beneforti P, et al.: Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord disease. Scand J Urol Nephrol 1998, 32:333–334.

    Google Scholar 

  43. Giannantoni A, DiStasi SM, Steven RL, et al.: Intravesical capsaicin vs resiniferatoxin in patients with detrusor hyperreflexia: a perspective, randomized study. J Urol 2002, 167:1710–1714.

    Article  PubMed  CAS  Google Scholar 

  44. Lazzeri M, Spinelli M, Beneforti P: Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized, placebo-controlled study. J Urol 2000, 164:676–679.

    Article  PubMed  CAS  Google Scholar 

  45. Lazzeri M, Beneforti P, Benaim G: Intravesical capsaicin for the treatment of interstitial cystitis: a randomized, placebo-controlled study. J Urol 1996, 156:947–952.

    Article  PubMed  CAS  Google Scholar 

  46. Payne CK, Mosbaugh PG, Forrest JB, et al.: Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo-controlled trial. J Urol 2005, 173:1592–1594.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Urology Center, 509 North Elam Avenue, 27403, Greensboro, NC, USA

    Robert J. Evans MD

Authors
  1. Robert J. Evans MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evans, R.J. Intravesical therapy for overactive bladder. Curr Bladder Dysfunct Rep 1, 40–44 (2006). https://doi.org/10.1007/s11884-006-0006-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-006-0006-4

Keywords

Search

Navigation